ArticleInfectious agents and cancer2026
Knowledge of cervical cancer and uptake of HPV vaccine among in-school adolescent girls in Kwara State, Nigeria.
Article in Infectious agents and cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer ranks as the second most common malignancy among Nigerian women, contributing heavily to preventable mortality, particularly in low-resource settings. HPV infection is the primary cause, and vaccination provides an effective prevention strategy. However, coverage in Nigeria remains critically low. Understanding knowledge and barriers among adolescent girls is imperative for designing interventions. This study explored these determinants among in-school girls in Kwara State.
methodsThis cross-sectional study surveyed 628 adolescent girls aged 9-14 years across rural, semi urban and urban LGAs in Kwara State. Multistage sampling included, random LGA selection, random school selection (7 public, 5 private per LGA), and systematic student sampling. Data were collected via comprehensive interviewer-administered questionnaires covering demographics, cervical cancer/HPV knowledge, barriers, and vaccine uptake. Analysis used STATA v18 with descriptive statistics and logistic regression with robust standard errors to identify predictors.
resultsMean age was 12.4 years (SD:1.7); 68.0% were in junior high school and 53.3% attended public schools. Overall knowledge levels were notably low: only 3.2% had good knowledge, 36.8% fair, and 60.0% poor. None of the participants had received the HPV vaccine. Major barriers included lack of awareness (82.2%), cost (76.0%), fear of side effects (71.2%), limited facility access (71.7%), and unawareness of vaccination sites (70.5%). Encouragingly, willingness to receive the vaccine was expressed by 71.2%. Fully adjusted logistic regression revealed that Muslim respondents had higher intention versus Christians (aOR = 1.61, 95%CI:1.12-2.33, p = 0.01). Location, age, school type, education level, and risk perception were not found to be significant predictors.
conclusionThis study exposes a critical disconnect between high willingness to vaccinate and profound knowledge deficits alongside substantial structural barriers. The complete absence of prior vaccinations underscores missed healthcare opportunities. To bridge this gap, targeted school-based health education leveraging teachers and healthcare workers is urgently needed to dispel myths about side effects and disseminate accurate information. Simultaneously, policy-driven strategies such as subsidizing vaccine costs, integrating vaccination into routine school health programs, and deploying mobile outreach to remote communities are essential to overcome financial and geographical obstacles. Translating favorable intentions into tangible uptake is critical for reducing Nigeria's future cervical cancer burden. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.